EuBiologics Co., Ltd. (KOSDAQ:206650)
South Korea · Delayed Price · Currency is KRW 7,950.00
+10.00 (0.13%)
Nov 4, 2026, 3:30 PM KST
EuBiologics Revenue
In the year 2024, EuBiologics had annual revenue of 96.04B KRW with 38.45% growth. EuBiologics had revenue of 26.89B in the quarter ending December 31, 2023, with 54.38% growth. That makes EuBiologics the 25,282nd largest company in the world by revenue and 1,472nd in South Korea.
Revenue
96.04B
Revenue Growth
+62.39%
P/S Ratio
2.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
292.18B
Revenue by Geography
- Overseas 66.86B 96.4%
- South Korea 2.51B 3.6%
Fiscal year ended Dec 31, 2023 See the full EuBiologics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 96.04B | 26.67B | 38.45% |
| Dec 31, 2023 | 69.37B | 13.90B | 25.06% |
| Dec 31, 2022 | 55.47B | 16.08B | 40.83% |
| Dec 31, 2021 | 39.38B | 10.90B | 38.24% |
| Dec 31, 2020 | 28.49B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| JW Holdings | 1.01T |
| Dong-A ST | 860.94B |
| Suheung | 765.90B |
| Huons | 607.75B |
| Ildong Pharmaceutical | 582.33B |
| Samjin Pharmaceuticals | 274.03B |
| Whan In Pharm | 273.47B |
| HLB Pharmaceutical | 251.95B |